EXPERIENCE OF NIFURATEL USAGE IN COMPLEX TREATMENT OF CHRONIC SPECIFIC BACTERIAL FIBROUSE AND CALCULOUS PROSTATITIS ASSOCIATED WITH TRICHOMONIASIS AND CANDIDOSIS
{"title":"EXPERIENCE OF NIFURATEL USAGE IN COMPLEX TREATMENT OF CHRONIC SPECIFIC BACTERIAL FIBROUSE AND CALCULOUS PROSTATITIS ASSOCIATED WITH TRICHOMONIASIS AND CANDIDOSIS","authors":"Юрий Заседа","doi":"10.37321/ujmh.2018.01-02","DOIUrl":null,"url":null,"abstract":"The aim of the study was to analyze the effi cacy of the drug “Macmiror” (active substance – nifuratel) in the treatment of chronic specifi c bacterial fi brous and calculous prostatitis associated with trichomoniasis and candidiasis.Materials and methods. The study was conducted on 50 patients of the “Clinic “Men’s Health”, suff ering from chronic specifi c bacterial fi brous and calculous prostatitis (mixed infection: trichomonadial-bacterial-candidiasis associates of various structure). As methods of research, in addition to the standard complex, the following were chosen: IN POUCH TV-test; PCR method; sonographic examination ofthe prostate and spermogram.Results of the study. Patients who completed the study were treated with chronic specifi c bacterial fi brous and calculous prostatitis (N41.1) for 14 days, according to the following therapeutic model: oral administration of nifuratel as part of the “Macmiror” preparation at a total dosage of 1200 mg per day (6 tablets of 200 mg) divided into 3 doses and physiotherapy.Conclusions. A general (in relation to diff erent types and combinations of infectious agents) of the therapeutic model has been established at a level of 71% to 100%. Treatment had absolute (clinical and laboratory) effi cacy against isolated Candida spp.; absolute clinical effi cacy and 71-85% laboratory effi cacy against isolated Trichomonas vaginalis; 92% clinical and 76-84% laboratory effi cacy against the combination of these infectious agents; 92% clinical and 80% laboratory effi cacy against the combination of these infectious agents and non-specifi c bacterial fl ora, as the etiological factors of chronic specifi c bacterial prostatitis.","PeriodicalId":204320,"journal":{"name":"Men’s Health, Gender and Psychosomatic Medicine","volume":"43 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Men’s Health, Gender and Psychosomatic Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37321/ujmh.2018.01-02","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The aim of the study was to analyze the effi cacy of the drug “Macmiror” (active substance – nifuratel) in the treatment of chronic specifi c bacterial fi brous and calculous prostatitis associated with trichomoniasis and candidiasis.Materials and methods. The study was conducted on 50 patients of the “Clinic “Men’s Health”, suff ering from chronic specifi c bacterial fi brous and calculous prostatitis (mixed infection: trichomonadial-bacterial-candidiasis associates of various structure). As methods of research, in addition to the standard complex, the following were chosen: IN POUCH TV-test; PCR method; sonographic examination ofthe prostate and spermogram.Results of the study. Patients who completed the study were treated with chronic specifi c bacterial fi brous and calculous prostatitis (N41.1) for 14 days, according to the following therapeutic model: oral administration of nifuratel as part of the “Macmiror” preparation at a total dosage of 1200 mg per day (6 tablets of 200 mg) divided into 3 doses and physiotherapy.Conclusions. A general (in relation to diff erent types and combinations of infectious agents) of the therapeutic model has been established at a level of 71% to 100%. Treatment had absolute (clinical and laboratory) effi cacy against isolated Candida spp.; absolute clinical effi cacy and 71-85% laboratory effi cacy against isolated Trichomonas vaginalis; 92% clinical and 76-84% laboratory effi cacy against the combination of these infectious agents; 92% clinical and 80% laboratory effi cacy against the combination of these infectious agents and non-specifi c bacterial fl ora, as the etiological factors of chronic specifi c bacterial prostatitis.